November 23, 2020

The Niche

Knoepfler lab stem cell blog

FT500

7 min read

IPS cell research is a growing area of promise for regenerative medicine. These stem cells, also known as iPSCs or more formally as Induced Pluripotent Stem Cells, are engineered cells that are programmed to function the same way as embryonic stem cells. They can be differentiated into possibly any type of cell that is needed for therapeutic purposes. Since iPSC production was first reported by Shinya Yamanaka using mouse and human cells in 2006 and 2007, respectively, cells from a whole host of species have …Read More

3 min read

There’s nothing like stem cell good news and interesting publications to perk one up on a Monday. Enjoy. What recent papers have struck you as exciting? Novel stem cell-based cancer approaches (Part 1) It was exciting when Fate Therapeutics got the first induced pluripotent stem cell (IPSC) IND in the U.S. for their IPSC-derived natural killer cell (NK) product. Now in another milestone the first patient has received the investigational NK therapy at UC San Diego. From UCSD, “After 10 years in remission, Derek Ruff’s cancer …Read More

2 min read

In the past month or two there has been a steady stream of good news in the stem cell and regenerative medicine world. Here are three examples. Fate Therapeutics announced the first US IND for an induced pluripotent stem cell (IPSC)-related product. Its cleared product, FT500, is an off-the-shelf natural killer-based cancer immunotherapy. I expect more to come in the next couple years so good news now and likely more to come. IPSC-based trials are picking up in Japan too with trials related to …Read More